Autopsy report · NCT05618691

A Study of GFH312 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication (IC)

“The study was terminated by sponsor for reasons of adjusted clinical development strategy.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Zhejiang Genfleet Therapeutics Co., Ltd.

Sponsor type

Industry

Conditions

Intermittent Claudication; Peripheral Artery Disease

Interventions

GFH312; Placebo

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Study of CX1106 in Patients With Advanced Head and Neck Squamous Cell Carcinoma
  “The study was terminated voluntarily by the sponsor due to changes in clinical development strategy.” (94% match in meaning)
• A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors
  “The study was terminated due to the sponsor's research and development strategy adjustment.” (89% match in meaning)
• Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers
  “The study was terminated due to the sponsor's decision to discontinue the clinical trial.” (85% match in meaning)
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LB4330 in Patients With Advanced Solid Tumors（MEETCD8-001）
  “Due to adjustments in the sponsor's development strategy, it has been decided to terminate the study.” (85% match in meaning)
• An Evaluation of the Erchonia Laser As a Non-Invasive Treatment to Improve the Appearance of Skin Laxity
  “The study was terminated early due to sponsor decision unrelated to safety or efficacy findings” (85% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.